Release Date: 28/02/13 14:30 Summary: Interim Results 2013 and Fund Update Price Sensitive: Yes Download Document 92.6KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%